Line Bjørge

Haukeland University Hospital — Norway

Medicine · Health Sciences

50h-index9.0kcitations310works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(109), Endometrial and Cervical Cancer Treatments(44), Pregnancy and preeclampsia studies(37), PARP inhibition in cancer therapy(29), Cancer-related molecular mechanisms research(26)

Publications300 total

Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer
npj Genomic Medicine·2025Open Access
sFlt-1 expression at the maternal-fetal interface and in maternal serum is not coregulated and show divergent upregulation in preeclampsia subtypes
Placenta·2025
Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors
Cell Reports Medicine·2025· 3 citedOpen Access
A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel
Therapeutic Advances in Medical Oncology·2025Open Access
1204P Feasibility of RNA-seq on FFPE tissues to identify survival-associated transcriptomic subtypes in ovarian cancer
Annals of Oncology·2025
Establishment of a humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluation of combination immunotherapy
2025Open Access
Empowerment and quality of life in gynecological cancer survivors: Outcomes from a multicenter quasi‐experimental cohort study from Norway (the LETSGO trial)
Cancer·2025· 1 citedOpen Access
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients
British Journal of Cancer·2025· 2 citedOpen Access
Prognostic Value of an Integrated Human Papillomavirus and Immunoscore Model to Predict Survival in Vulva Squamous Cell Carcinoma
Modern Pathology·2025Open Access
SupplementaryGeneTable S1 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2025Open Access
Supplementary Material from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2025Open Access
4935 A phase 3 study of pembrolizumab + concurrent chemoradiotherapy for high-risk locally advanced cervical cancer: interim analysis 2 findings
Radiotherapy and Oncology·2025
SupplementaryGeneTable S1 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2025Open Access
Supplementary Material from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2025Open Access
Systems epigenetic approach towards non-invasive breast cancer detection
Nature Communications·2025· 8 citedOpen Access
Hereditary antithrombin deficiency and venous thrombosis in pregnancy–results of a retrospective multicenter study
Journal of Thrombosis and Haemostasis·2025· 2 cited
The Impact Of The LETSGO Personalized Follow-Up Model On Empowerment And Quality Of Life In Gynaecological Cancer Survivors: A Multicenter Quasi-Experimental Study
International Journal of Gynecological Cancer·2025· 1 cited
Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐ <scp>CD</scp> 73/anti‐ <scp>PD</scp> ‐ <scp>L</scp> 1 immunotherapy in arm A of the <scp>NSGO</scp> ‐ <scp>OV</scp> ‐ <scp>UMB1</scp> / <scp>ENGOT</scp> ‐ <scp>OV</scp> 30 trial
Molecular Oncology·2025· 3 citedOpen Access
A 3D ovarian cancer metastasis model using a decellularized peritoneal matrix to study therapy response
2024
Figure 4 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
page 1 of 15Next →

Frequent Co-authors

Hoda Anton‐Culver(11), Diana Eccles(11), Jonathan P. Tyrer(10), Ralf Bützow(10), Ian Campbell(10), Graham G. Giles(10), Marc T. Goodman(10), Estrid Høgdall(10), Diether Lambrechts(10), Helga B. Salvesen(10), Elisa V. Bandera(9), Matthias W. Beckmann(9), Daniel W. Cramer(9), Thilo Dörk(9), Claus Høgdall(9), Lambertus A. Kiemeney(9), Camilla Krakstad(9), Douglas A. Levine(9), Jenny Chang‐Claude(9), Maria Bisogna(8)